Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke explains how the company is combatting the leading, global cause of death with its novel, personalised therapy pipeline. Prescient has a suite of anti-cancer treatments in the works, and it's leveraging CAR-T therapies to improve its patients' outcomes. At the forefront of the company's portfolio is its OmniCAR platform, which combines the cancer-killing capabilities of a T-cell with the control and pharmacology of a drug. Yatomi-Clarke says interest in the company's targeted therapies is growing, and there's enough cash in the bank to take the company through what's shaping up as "a very busy year".
Prescient Therapeutics is making game-changing cancer therapies for a global market
